Navigation Links
Adenovector in Medical News

GenVec Announces Second Quarter 2009 Results Conference Call

... use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. A...

GenVec Receives Grant for Malaria Vaccine Program

...llaborating with the U.S. Naval Medical Research Center (NMRC) to apply its adenovector technology to the development of malaria vaccine candidates. Abou..., rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malar...

Cardium Receives Preliminary Notification of Inclusion in the Russell 3000(R) Index and Russell Global(R) Index

...vere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-B (PDGF-B). Excellarate(TM) is initially being developed to be administered once or tw...

Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting

...ss. To accomplish localized sustained production, Excellarate comprises an adenovector with a gene encoding human platelet-derived growth factor-B (Ad5PDGF-B), in...), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-B (PDGF-B). ...

Cardium Reports on First Quarter 2009 Financial Results and Recent Developments

...vere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate(TM) is initially being developed to be administered once or ...

Cardium Reports on New Excellarate(TM) Product Formulations to Expand Commercialization Potential Into Multiple Wound Healing Applications

...vere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-B (PDGF-B). Excellarate(TM) is initially being developed to be administered once or tw...

Cardium Provides Update Regarding Exchange Listing Compliance Plan Accepted by NYSE Amex

...vere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate(TM) is initially being developed to be administered once or ...

Cardium's InnerCool Announces Journal of Neurotrauma Highlights Hypothermia Therapy's Role in Post Cardiac Arrest, and Traumatic Brain and Spinal Cord Injury Patients

...vere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate(TM) is initially being developed to be administered once or ...

Cardium Reports on Recent Highlights, Financial Results and 2009 Outlook

...vere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate(TM) is initially being developed to be administered once or ...

Cardium's Exchange Listing Compliance Plan Accepted by NYSE Alternext US

...vere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate(TM) is initially being developed to be administered once or ...
Adenovector in Medical Technology

GenVec Presents Research on New Ad35 Adenovector at ARVO

GAITHERSBURG, Md.--(BUSINESS WIRE)--May 10, 2007 - GenVec, Inc. (Nasdaq:GNVC) today announced pre-clinical research demonstrating the ability of the Company's new adenovector, Ad35, to induce and sustain protein production in the eye. Lisa L. Wei, Ph.D., GenVec's Director of Pre-Clinical Research, ...

TNFerade(TM) Phase III Data Presented at ASCO

... use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. A...

Cardium Announces Completion of Patient Recruitment in Phase 2b Clinical Trial of Excellarate(TM) for the Potential Treatment of Diabetic Foot Ulcers

...evere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-B (PDGF-B). Excellarate(TM) is initially being developed to be administered once or twi...

Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack

...vere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate(TM) is initially being developed to be administered once or ...

Cardium's InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology

...vere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate(TM) is initially being developed to be administered once or ...

GenVec Announces Multiple Presentations at the American Society of Tropical Medicine and Hygiene Meeting

...m preclinical research through ongoing clinical studies using GenVec's core adenovector technology. (Logo: http://www.newscom.com/cgi-bin/prnh/20081205/...ancer, head and neck cancer, and melanoma. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malar...

Cardium Reports on Second Quarter 2008 Highlights and Financial Results

...evere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate(TM) is initially being developed to be administered once or t...

Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities

...evere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate is initially being developed to be administered once or twice...

Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack

...evere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate is initially being developed to be administered once or twice...

Cardium and Tissue Repair Company's Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.

...of severe chronic diabetic wounds. TRC's lead product candidate, Excellarate, is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate is initially being developed to be administered once or twice...
Adenovector in Biological Technology

GenVec Reports Second Quarter 2009 Financial Results

... use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. A...

Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors

... Surg, 2005, May; 87(5): 1059-1068) demonstrated that local delivery of an adenovector encoding BMP-2 (AdBMP-2) in a collagen matrix rapidly induced new bone form... Surg, 2005, May; 87(5): 1059-1068) demonstrated that local delivery of an adenovector encoding BMP-2 (AdBMP-2) in a collagen matrix rapidly induced new bone form...

GenVec Expands Contract Supporting Malaria Vaccine Program

... use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. A...

GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants

... use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. A...

Cardium Announces Conference Call and Webcast to Review Recent Developments and Future Plans for the Excellarate(TM) Clinical Development Program

...vere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-B (PDGF-B). Excellarate(TM) is initially being developed to be administered once or tw...

Cardium Completes $3.5 Million Credit Facility

...vere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate(TM) is initially being developed to be administered once or ...

Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine

...vere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate(TM) is initially being developed to be administered once or t...

Cardium Announces Retirement of Director

...vere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate(TM) is initially being developed to be administered once or ...

International Robotic Urology Symposium Reports on Benefits of Cooling During Robotic-Assisted Prostate Surgery and Introduces InnerCool's New Investigational UroCool System

...vere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate(TM) is initially being developed to be administered once or ...

Cardium's InnerCool Announces First Patient Treated With New Tissue-Specific UroCool(TM) System in Robotic-Assisted Prostate Surgery Study

...vere chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate(TM) is initially being developed to be administered once or ...
Other Tags
(Date:8/1/2014)... The Judicial Panel on Multidistrict Litigation ... therapy caused strokes, heart attacks, and other injuries in ... F. Kennelly as the transferee judge and ordered what ... federal court. , As one of his first organizing ... of attorneys who will move the litigation forward on ...
(Date:8/1/2014)... central role in regulating appetite and whole-body metabolism. A ... control of food intake and body weight, but the ... unclear. A new study in the ... in a type of neuron known as pro-opiomelanocortin (POMC) ... diet. Sabrina Diano and colleagues at Yale University ...
(Date:8/1/2014)... 2014 Stryker hip lawsuits ( ... 2012 Rejuvenate and ABG II Modular-Neck Hip Stem ... Bergen County Superior Court, Bernstein Liebhard LLP reports. ... Court has issued a Final Amended Stipulated ... hard copy and electronic materials produced by any ...
(Date:8/1/2014)... CLEVELAND, Ohio In a first-of-its-kind study, researchers at ... found that lap infants may be at greater risk ... analyzed pediatric medical emergencies on flights worldwide between January ... deaths occurred in children under the age of 2. ... MedAire to characterize the rare event of an in-flight ...
(Date:8/1/2014)... Vegas, NV (PRWEB) August 01, 2014 ... and opportunities for independent community pharmacies. At ThoughtSpot ... pharmacists are equipped with practices and resources to ... Session, AmerisourceBergen leaders focused on critical issues to ... learn, optimize and grow. , ThoughtSpot show ...
Breaking Medicine News(10 mins):Health News:Judge Kennelly Appoints Attorney Michelle Kranz to the Plaintiffs’ Executive Committee in the Testosterone Replacement Therapy MDL 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:New research characterizes in-flight pediatric deaths 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5
(Date:7/31/2014)... long-term follow-up study (HPV-023; NCT00518336) shows the ... human papilloma virus (HPV) vaccine Cervarix. Women ... followed for more than nine years, and ... 100%. This is the longest follow-up report ... https://www.landesbioscience.com/journals/vaccines/article/29532/ for the full paper. , ...
(Date:7/31/2014)... in German . ... similar to a sponge that soaks up liquids. Hence, ... or greenhouse gases. However, loading of many MOFs is ... (KIT) now report in Nature Communications that ... surface. This can be prevented by water-free synthesis and ...
(Date:7/31/2014)... effect in 1839, humankind has sought to further understand ... purposes. In a new research report published in the ... , scientists may have uncovered a new method ... a naturally occurring combination of lipids that have been ... and across speciessuggests that this specific natural combination of ...
Breaking Biology News(10 mins):Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3Free pores for molecule transport 2Scientists shine bright new light on how living things capture energy from the sun 2
Other Contents